Drug Trial Radar · NCT03393013
A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis
Last checked: Nov 20, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
69
Actual
Start
Feb 20, 2018
Primary completion
Aug 4, 2022
Study completion Aug 4, 2022
Sponsor
- Lead sponsor
- Kezar Life Sciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 8, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a Phase 1b/2, multi-center study in which patients received KZR-616, administered as a subcutaneous (SC) injection weekly for 13 weeks (Phase 1b) or 24 weeks (Phase 2).
Conditions
- Lupus Nephritis
- Systemic Lupus Erythematosus
Interventions
KZR-616Drug
Subcutaneous Injection of KZR-616
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Number of Patients Who Experienced at Least One Treatment-Related Treatment-Emergent Adverse EventTime frame: 25 weeks
- Phase 2: Number of Patients With Lupus Nephritis With a 50% Reduction in UPCRTime frame: 24 weeks
Locations
36 sites in 8 countries. Site status is shown where the registry gives one.
Academic Medical Research Institute
Los Angeles, California
Inland Rheumatology Clinical Trials, Inc.
Upland, California
SouthCoast Research Center, Inc.
Miami, Florida
Hope Clinical Trials, Inc.
Miami, Florida
Omega Research Maitland
Orlando, Florida
Arthritis Center, Inc
Palm Harbor, Florida
Advent Health Medical Group
Tampa, Florida
University of Iowa
Iowa City, Iowa
Northwell Health
Great Neck, New York
NYU Langone Orthopedic Center - Seligman Center for Advanced Therapeutics
New York, New York
University of Rochester Medical Center
Rochester, New York
The Ohio State University Wexner Medical Center
Columbus, Ohio
SC Nephrology & Hypertension Center, Inc.
Orangeburg, South Carolina
Ramesh C. Gupta, MD
Memphis, Tennessee
MedResearch, Inc.
El Paso, Texas
Accurate Clinical Research, Inc.
Houston, Texas
Accurate Clinical Management, LLC
Houston, Texas
Monash Health
Clayton, Victoria, Australia
The Royal Melbourne Hospital
Parkville, Victoria, Australia
Centro Integral de Reumatologia de Caribe CIRCARIBE S.A.S
Barranquilla, Atlántico, Colombia
Clinica de la Costa
Barranquilla, Atlántico, Colombia
Medicity SAS
Santander, Bucaramanga, Colombia
Servimed S.A.S.
Bucaramanga, Santander Department, Colombia
Clinica de Artritis Temprana
Cali, Valle del Cauca Department, Colombia
Instituto Nacional de Cardiología Ignacio Chavez
Mexico City, Mexico
Instituto Nacional de Ciencias Médicas y Nutricion "Salvador Zubiran"
Mexico City, Mexico
Centro Integral de Reumatologia SA de CV
Guadalajara, Jalisco, Mexico
Hospital Universitario Dr José Eleuterio Gonzalez
Monterrey, Nuevo León, Mexico
Investigaciones Clinicas SAC
Lima, Peru
Unidad de Investigacion en Reumatologia e Inmunologia Clinica San Juan Bautista
Lima, Peru
Centro de Investigación Clínica Trujillo E.I.R.L/ Clínica Peruano Americana S.A.
Trujillo, La Libertad, Peru
Bioclinica
Lodz, Poland
Kuzbass Clinical Hospital
Kemerovo, Russia
Medical Center Revma-Med
Kemerovo, Russia
Tolyatti City Clinical Hospital #1
Tolyatti, Russia
Harmoniya Krasy
Kyiv, Kyiv Governorate, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.